Individuals with this Bw4 variant harbored KIR3DL1+ NK cells with inferior degranulation and cytokine release responses to leukemic cells, which may contribute to the poor survival after AML immunotherapy. This evidence concerns the gene KIR3DL1 and acute myeloid leukemia.